Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA
14 sept. 2022 06h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
16 août 2022 06h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
25 juil. 2022 10h57 HE
|
Revive Therapeutics Ltd.
TORONTO, July 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
24 juin 2022 11h41 HE
|
Revive Therapeutics Ltd.
TORONTO, June 24, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
06 juin 2022 13h54 HE
|
Revive Therapeutics Ltd.
TORONTO, June 06, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation
31 mai 2022 07h00 HE
|
Revive Therapeutics Ltd.
WHO reports 650 probable cases of acute hepatitis of unknown aetiology in children from 33 countries Company received FDA orphan drug designation for Bucillamine in the prevention of...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
26 mai 2022 10h15 HE
|
Revive Therapeutics Ltd.
The Company received positive comments from the FDA to determine potential new clinical endpoints to support Emergency Use Authorization TORONTO, May 26, 2022 (GLOBE NEWSWIRE) -- Revive...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
16 mai 2022 10h48 HE
|
Revive Therapeutics Ltd.
TORONTO, May 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
25 avr. 2022 16h42 HE
|
Revive Therapeutics Ltd.
TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19
18 avr. 2022 09h43 HE
|
Revive Therapeutics Ltd.
TORONTO, April 18, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...